Bristol-Myers Squibb
This article was originally published in The Gray Sheet
Executive Summary
Senior VP-Strategy & Organizational Effectiveness Peter Dolan is named president and a member of the board of directors, positioning him as a likely heir to current Chairman and CEO Charles Heimbold. Dolan is credited with building value in each of the company's major business segments, including medical devices. Other key appointments in the senior management team announced Jan. 20 include Senior VP and President-Worldwide Medicines Group Donald Hayden to executive VP responsible for implementing an e-business strategy and managing strategic planning. In addition, President-U.S. Medicines Richard Lane is appointed president-worldwide medicines group, reporting to Dolan. Peter Ringrose becomes chief scientific officer, reporting to Lane. Ringrose continues as president of the Pharmaceutical Research Institute
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.